Log In
Print
BCIQ
Print
Print this Print this
 

Relday, risperidone

  Manage Alerts
Collapse Summary General Information
Company Durect Corp.
DescriptionSubcutaneous drug delivery system plus a subcutaneous once-monthly formulation of risperidone formulated using Durect's SABER controlled-release technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation
Partner Zogenix Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$105.3M

$2.3M

$103.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today